BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 34548309)

  • 1. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant,
    Jänne PA; Baik C; Su WC; Johnson ML; Hayashi H; Nishio M; Kim DW; Koczywas M; Gold KA; Steuer CE; Murakami H; Yang JC; Kim SW; Vigliotti M; Shi R; Qi Z; Qiu Y; Zhao L; Sternberg D; Yu C; Yu HA
    Cancer Discov; 2022 Jan; 12(1):74-89. PubMed ID: 34548309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
    Yu HA; Goto Y; Hayashi H; Felip E; Chih-Hsin Yang J; Reck M; Yoh K; Lee SH; Paz-Ares L; Besse B; Bironzo P; Kim DW; Johnson ML; Wu YL; John T; Kao S; Kozuki T; Massarelli E; Patel J; Smit E; Reckamp KL; Dong Q; Shrestha P; Fan PD; Patel P; Sporchia A; Sternberg DW; Sellami D; Jänne PA
    J Clin Oncol; 2023 Dec; 41(35):5363-5375. PubMed ID: 37689979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic
    Yu HA; Yang JC; Hayashi H; Goto Y; Felip E; Reck M; Vigliotti M; Dong Q; Cantero F; Fan PD; Kanai M; Sternberg DW; Jänne PA
    Future Oncol; 2023 Jun; 19(19):1319-1329. PubMed ID: 37212796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.
    Yonesaka K; Tanizaki J; Maenishi O; Haratani K; Kawakami H; Tanaka K; Hayashi H; Sakai K; Chiba Y; Tsuya A; Goto H; Otsuka E; Okida H; Kobayashi M; Yoshimoto R; Funabashi M; Hashimoto Y; Hirotani K; Kagari T; Nishio K; Nakagawa K
    Clin Cancer Res; 2022 Jan; 28(2):390-403. PubMed ID: 34921025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC.
    Yu HA; Baik C; Kim DW; Johnson ML; Hayashi H; Nishio M; Yang JC; Su WC; Gold KA; Koczywas M; Smit EF; Steuer CE; Felip E; Murakami H; Kim SW; Su X; Sato S; Fan PD; Fujimura M; Tanaka Y; Patel P; Sternberg DW; Sellami D; Jänne PA
    Ann Oncol; 2024 May; 35(5):437-447. PubMed ID: 38369013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced
    Mok T; Jänne PA; Nishio M; Novello S; Reck M; Steuer C; Wu YL; Fougeray R; Fan PD; Meng J; Sternberg DW; Esker S; Yu HA
    Future Oncol; 2024 May; 20(15):969-980. PubMed ID: 38095056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd.
    Haikala HM; Lopez T; Köhler J; Eser PO; Xu M; Zeng Q; Teceno TJ; Ngo K; Zhao Y; Ivanova EV; Bertram AA; Leeper BA; Chambers ES; Adeni AE; Taus LJ; Kuraguchi M; Kirschmeier PT; Yu C; Shiose Y; Kamai Y; Qiu Y; Paweletz CP; Gokhale PC; Jänne PA
    Cancer Res; 2022 Jan; 82(1):130-141. PubMed ID: 34548332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial.
    Krop IE; Masuda N; Mukohara T; Takahashi S; Nakayama T; Inoue K; Iwata H; Yamamoto Y; Alvarez RH; Toyama T; Takahashi M; Osaki A; Saji S; Sagara Y; O'Shaughnessy J; Ohwada S; Koyama K; Inoue T; Li L; Patel P; Mostillo J; Tanaka Y; Sternberg DW; Sellami D; Yonemori K
    J Clin Oncol; 2023 Dec; 41(36):5550-5560. PubMed ID: 37801674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC.
    Lim SM; Kim CG; Lee JB; Cho BC
    Cancer Discov; 2022 Jan; 12(1):16-19. PubMed ID: 35022206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive
    Yu HA; Paz-Ares LG; Yang JC; Lee KH; Garrido P; Park K; Kim JH; Lee DH; Mao H; Wijayawardana SR; Gao L; Hozak RR; Chao BH; Planchard D
    Clin Cancer Res; 2021 Feb; 27(4):992-1002. PubMed ID: 33046516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting HER3 to overcome EGFR TKI resistance in NSCLC.
    Chen Q; Jia G; Zhang X; Ma W
    Front Immunol; 2023; 14():1332057. PubMed ID: 38239350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors.
    Lu Y; Shimizu S; Sawamura R; Tajima N; He L; Lee M; Abutarif M; Shi R
    J Clin Pharmacol; 2023 Jan; 63(1):77-90. PubMed ID: 36053771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study.
    Oliveira M; Falato C; Cejalvo JM; Vila MM; Tolosa P; Salvador-Bofill FJ; Cruz J; Arumi M; Luna AM; Guerra JA; Vidal M; Martínez-Sáez O; Paré L; González-Farré B; Sanfeliu E; Ciruelos E; Espinosa-Bravo M; Pernas S; Izarzugaza Y; Esker S; Fan PD; Parul P; Santhanagopal A; Sellami D; Villacampa G; Ferrero-Cafiero JM; Pascual T; Prat A
    Ann Oncol; 2023 Aug; 34(8):670-680. PubMed ID: 37211044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.
    Ahn MJ; Han JY; Lee KH; Kim SW; Kim DW; Lee YG; Cho EK; Kim JH; Lee GW; Lee JS; Min YJ; Kim JS; Lee SS; Kim HR; Hong MH; Ahn JS; Sun JM; Kim HT; Lee DH; Kim S; Cho BC
    Lancet Oncol; 2019 Dec; 20(12):1681-1690. PubMed ID: 31587882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC.
    Yonesaka K; Takegawa N; Watanabe S; Haratani K; Kawakami H; Sakai K; Chiba Y; Maeda N; Kagari T; Hirotani K; Nishio K; Nakagawa K
    Oncogene; 2019 Feb; 38(9):1398-1409. PubMed ID: 30302022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.
    Nishio M; Horiike A; Murakami H; Yamamoto N; Kaneda H; Nakagawa K; Horinouchi H; Nagashima M; Sekiguchi M; Tamura T
    Lung Cancer; 2015 Jun; 88(3):275-81. PubMed ID: 25891541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
    Modi S; Park H; Murthy RK; Iwata H; Tamura K; Tsurutani J; Moreno-Aspitia A; Doi T; Sagara Y; Redfern C; Krop IE; Lee C; Fujisaki Y; Sugihara M; Zhang L; Shahidi J; Takahashi S
    J Clin Oncol; 2020 Jun; 38(17):1887-1896. PubMed ID: 32058843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.
    Shimizu T; Yonesaka K; Hayashi H; Iwasa T; Haratani K; Yamada H; Ohwada S; Kamiyama E; Nakagawa K
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):489-495. PubMed ID: 28144730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.
    Shimizu T; Sands J; Yoh K; Spira A; Garon EB; Kitazono S; Johnson ML; Meric-Bernstam F; Tolcher AW; Yamamoto N; Greenberg J; Kawasaki Y; Zebger-Gong H; Kobayashi F; Phillips P; Lisberg AE; Heist RS
    J Clin Oncol; 2023 Oct; 41(29):4678-4687. PubMed ID: 37327461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Nakagawa K; Garon EB; Seto T; Nishio M; Ponce Aix S; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Imamura F; Yoh K; Shih JY; Au KH; Moro-Sibilot D; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M;
    Lancet Oncol; 2019 Dec; 20(12):1655-1669. PubMed ID: 31591063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.